Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H37N5O10 |
| Molecular Weight | 483.5139 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 15 / 15 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
InChI
InChIKey=SKKLOUVUUNMCJE-FQSMHNGLSA-N
InChI=1S/C18H37N5O10/c19-2-6-11(26)12(27)9(23)17(30-6)32-15-4(20)1-5(21)16(14(15)29)33-18-13(28)8(22)10(25)7(3-24)31-18/h4-18,24-29H,1-3,19-23H2/t4-,5+,6+,7+,8-,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+/m0/s1
| Molecular Formula | C18H37N5O10 |
| Molecular Weight | 483.5139 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 15 / 15 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: www.drugfuture.com/mt/bekanamycin-sulfate.pdfCurator's Comment: description was created based on several sources, including:
http://www.drugfuture.com/chemdata/Kanamycin.html
https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000902_022729_FI.pdf&retry=0&sys=m0b1l3
Sources: www.drugfuture.com/mt/bekanamycin-sulfate.pdf
Curator's Comment: description was created based on several sources, including:
http://www.drugfuture.com/chemdata/Kanamycin.html
https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000902_022729_FI.pdf&retry=0&sys=m0b1l3
Bekanamycin is an aminoglycoside and is a congener of kanamycin. It is given topically as the sulfate for the treatment of eye infections. It is reported
to be more toxic than kanamycin A. Antibiotic complex produced by Streptomyces kanamyceticus Okami & Umezawa from Japanese soil. There are no known interactions with other drugs.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2363135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11459219 |
180.0 nM [Kd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Visucloben antibiotico Approved UseIt is used in the treatment of eye infections. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| In vitro and in vivo activities of ruthenium(II) phosphine/diimine/picolinate complexes (SCAR) against Mycobacterium tuberculosis. | 2013 |
|
| Antimycobacterial activity of phorbol esters from the fruits of Sapium indicum. | 2003-04 |
|
| Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. | 1993-09-24 |
|
| In vitro and in vivo susceptibility of atypical mycobacteria to various drugs. | 1981-09-01 |
|
| [Experimental study on renal tolerability of aminoglycosides butirosin and bekanamycin (author's transl)]. | 1980 |
|
| [Comparative studies on the problem of nephrotoxicity of the aminoglycosides: kanamycin, amikacin, butirosin and kanendomycin]. | 1976 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://imedi.it/visucloben-antibiotico
One drop 4 times per day
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26592740
B. subtilis 168 (strain I) and S. epidermidis ATCC 12228 (strain X) are both susceptible to Bekanamycin (MIC = 4 ug/mL and 0.5 ug/mL, respectively).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:15:40 GMT 2025
by
admin
on
Mon Mar 31 18:15:40 GMT 2025
|
| Record UNII |
15JT14C3GI
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C2363
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
||
|
WHO-ATC |
J01GB13
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
||
|
WHO-VATC |
QJ01GB13
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1520
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
PRIMARY | |||
|
4696-76-8
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
PRIMARY | |||
|
C001495
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
PRIMARY | |||
|
DB13673
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
PRIMARY | |||
|
439318
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
PRIMARY | |||
|
CHEMBL2105594
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
PRIMARY | |||
|
C65248
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
PRIMARY | |||
|
28098
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
PRIMARY | |||
|
15JT14C3GI
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
PRIMARY | |||
|
58549
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
PRIMARY | |||
|
2838
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
PRIMARY | |||
|
225-170-5
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
PRIMARY | |||
|
DTXSID8023185
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
PRIMARY | |||
|
m6599
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB05684MIG
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
PRIMARY | |||
|
100000086135
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
PRIMARY | |||
|
BEKANAMYCIN
Created by
admin on Mon Mar 31 18:15:40 GMT 2025 , Edited by admin on Mon Mar 31 18:15:40 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
Amount not specified.
|
||
|
IMPURITY -> PARENT |
Amount not specified.
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |